Credit: Boehringer Ingeheim. The high-concentration formultion (100mg/mL) is available as a prefilled syringe (40mg/0.4mL) or prefilled autoinjector. Cyltezo is an interchangeable biosimilar and can ...

The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of adalimumab-adbm (Cyltezo), a biosimilar of Humira, Boehringer Ingelheim announced. This ...

Please provide your email address to receive an email when new articles are posted on . As with the low-concentration (50 mg/mL) version of Cyltezo (adalimumab-adbm ...

(RTTNews) - Sandoz (SDZNY) has unveiled Hyrimoz or adalimumab citrate-free high concentration formulation (HCF; 100 mg/mL) in Europe. The medicine will become available to patients progressively ...

Boehringer Ingelheim has received the Food and Drug Administration’s blessing for the high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm), the company’s interchangeable ...

Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar SB5 and a high-concentration version. While 2023 is becoming ...

Altruist Biologics, an Innovent Biologics subsidiary and world-class contract development and manufacturing organization (CDMO), recently announced the launch of Altru-CON, a high-concentration ...

The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already approved. Both versions will launch in July 2023. Last week, ...

SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Prestige Biopharma IDC, the innovative drug research institute of Prestige Biopharma, announced that it has filed a patent for 'IDC224,' a ...

Altru-CON™ harnesses proprietary excipient blends and expertise to maximize drug delivery and stability through high-concentration formulation. The platform can reduce IND timelines to under nine ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, ...